Transcriptome-Guided Drug Repurposing Identifies Homoharringtonine (HHT) as a Candidate for Radiation-Induced Pulmonary Fibrosis
Mohamed El-Agamy Farh, Sang Yeon Kim, Sunjoo Park, Cui Ronglan, InSuk Sohn, Jaeho Cho, Carsten Ehrhardt · 2025
Read Transcriptome-Guided Drug Repurposing Identifies Homoharringtonine (HHT) as a Candidate for Radiation-Induced Pulmonary Fibrosis by Mohamed El-Agamy Farh, Sang Yeon Kim, Sunjoo Park, Cui Ronglan, InSuk Sohn, Jaeho Cho, Carsten Ehrhardt (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12736785.txt.
Description
The authors test whether an existing cancer drug, homoharringtonine, could treat lung scarring caused by radiation therapy. This scarring, called radiation-induced pulmonary fibrosis, burdens many patients who survive lung cancer treatment, and few proven drugs target it. The team uses a repurposing platform that matches gene activity patterns from injured lung models against a large library of drug signatures. The goal is to find compounds that reverse the scarring pattern.
The drug ranks among the top candidates and already holds approval as a protein synthesis blocker. In a lab model using human lung fibroblast cells, it cuts cell growth, blocks the shift into scar-forming cells, and lowers collagen buildup. It also suppresses two markers of the scarring process. Computer docking studies explore how it may act, and the team traces effects on two pathways that drive scarring. The authors present the drug as a candidate worth further testing.
Catalog record
| CREATOR | Mohamed El-Agamy Farh, Sang Yeon Kim, Sunjoo Park, Cui Ronglan, InSuk Sohn, Jaeho Cho, Carsten Ehrhardt |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 58 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |